OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On May 2, 2017, Oxford Immunotec Global PLC (the Registrant)
issued a press release announcing its financial results for the
first quarter of 2017.The full text of the press release and the
related attachment are furnished as Exhibit 99.1 hereto and
incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Item2.02, and Exhibit 99.1 hereto, shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Registrants filings under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such a filing.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Exhibit Description |
|
|
99.1 |
|
Press Release dated May 2, 2017, Oxford Immunotec |
|
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA. OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Recent Trading Information
OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) closed its last trading session up +0.03 at 15.42 with 79,047 shares trading hands.